FDA alerts asthmatics to drug safety risk.
Clare
C
Ellis
D000318:Adrenergic beta-Agonists / Q000009:adverse effects*; D000420:Albuterol / Q000009:adverse effects* / Q000031:analogs & derivatives*; D001249:Asthma / Q000188:drug therapy*; D003257:Consumer Product Safety; D006801:Humans; D011358:Product Surveillance, Postmarketing; D012449:Safety; D000068299:Salmeterol Xinafoate; D014481:United States; D014486:United States Food and Drug Administration
D000318:Adrenergic beta-Agonists; D000068299:Salmeterol Xinafoate; D000420:Albuterol